Key result
Candesartan cilexetil 16 mg once daily significantly reduced mean arterial pressure by 8 mmHg (95% CI 2.6-12.3) compared to placebo without compromising cardiac performance.
Why the study?
Does candesartan cilexetil improve systemic and forearm haemodynamics in patients with essential hypertension?
Population
22 patients with essential hypertension (diastolic blood pressure 100-114 mmHg)
Comparison
Candesartan cilexetil 16 mg once daily for 6 weeks vs Placebo once daily for 6 weeks
Design
RCT, randomized, crossover, double-blind, placebo-controlled
Follow-up
6 weeks
Authors
Loading...
Supports candesartan 16 mg daily for BP reduction in essential hypertension without cardiac compromise; extends haemodynamic evidence for AT1-receptor blockade.
RCT (n=22)
Double-blind
crossover
Does candesartan cilexetil improve systemic and forearm haemodynamics in patients with essential hypertension?
Mean Difference: 8 (95% CI 2.6–12.3)
Six weeks of treatment with candesartan cilexetil 16 mg daily induced systemic and forearm vasodilatation and reduced blood pressure without compromising cardiac performance.
Moshe Fridman (1999) conducted an RCT in essential hypertension (n=22). candesartan cilexetil vs. placebo was evaluated on mean arterial pressure (MD 8 mmHg reduction, 95% CI 2.6-12.3). Candesartan cilexetil 16 mg once daily significantly reduced mean arterial pressure by 8 mmHg (95% CI 2.6-12.3) compared to placebo without compromising cardiac performance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: